Integra LifeSciences Holdings Corporation (Nasdaq: IART), a global leader in medical technology, announces that it has entered into a definitive agreement to acquire Acclarent, Inc. from Ethicon, Inc., a Johnson & Johnson MedTech company for $275 million in cash at closing, subject to customary purchase price adjustments, and an additional $5 million upon the achievement of certain regulatory milestones. Acclarent is an innovator and market leader in ENT procedures and upon closing, Integra will be one of the leading providers of ENT products and technologies. Acclarent is headquartered in Irvine, California, and derives its revenues from U.S. product sales, which generated about $110 million in 2022 and gross margins in line with Integra’s company average.
Read the full article: Integra LifeSciences Announces Definitive Agreement to Acquire Acclarent® //
Source: https://www.globenewswire.com/news-release/2023/12/13/2795373/1063/en/Integra-LifeSciences-Announces-Definitive-Agreement-to-Acquire-Acclarent.html